Robert Z. Orlowski, MD from MD Anderson Cancer Center discusses if MRD negative patients can stop maintenance and continue treatment…
Browsing: Acute Lymphoblastic Leukemia
Habte Yimer, MD from Texas Oncology discusses Daratumumab studies have shown significant benefits and effective in combination with CyBorD at…
Gareth Morgan, MD from University of Arkansas for Medical Sciences discusses developing data will help clinicians and CAR-T cells are…
Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses MPD-RC 111 protocol for patients with polycythemia vera or…
Personal digital disease tracking enables patients and the multidisciplinary team managing their care to better monitor their disease. Speaking from…
Digital technologies can aid both patients and clinicians in managing a disease. Here, Nina Paton from The Christie NHS Foundation…
There is a lack of funding for research into certain cancer types, such as lung and pancreatic cancer, compared with…
Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Islam Elkonaissi of The Royal…
Exciting clinical updates for lung and pancreatic cancer were presented at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium…
In this presentation from the ‘Looking Closely at New Therapeutic Options for Hepatocellular Carcinoma’, Dr. Bruno Daniele discusses the latest…
In this presentation from the ‘Looking Closely at New Therapeutic Options for Hepatocellular Carcinoma’, Dr. Jordi Bruix discusses novel treatment…
In this presentation from the ‘Looking Closely at New Therapeutic Options for Hepatocellular Carcinoma’, Dr. Luigi Bolondi discusses the latest…
Joseph M. Connors, MD from British Colombia Cancer Agency discusses the progress that has been made combatting Hodgkins lymphoma and…
Robert Z. Orlowski, MD from MD Anderson Cancer Center discusses further research in Multiple Myeloma and adapting to a minimal…
John M. Burke, MD from Rocky Mountain Cancer Centers discusses new conjugate CD 79 and relapsed refractory B-Cell at the…
Aziz Nazha, MD from the Cleveland Clinic discusses predicting Survival Myelodysplastic Syndrome and using the Random Survival Forest Algorithm at…
Alok Khorana, MD from the Cleveland Clinic discusses studies in 2018 and CASSINI and Apixaban for the prevention of VTE…
Sattva S. Neelapu MD, from MD Anderson Cancer Center discusses beyond ZUMA-1 and evaluating Axi-Cel efficacy at the 2017 American…
Robert Z. Orlowski, MD, PhD, from The University of Texas MD Anderson Cancer Center discusses multiple myeloma studies for 2018…
The production of novel anti-cancer treatments has taken cancer therapy to a point that was previously unimaginable. Here, Jeff Evans,…
Joseph M. Connors, MD from British Colombia Cancer Agency discusses results of the Echelon-1 Trial and new chemotherapy that is…
When helping patients through their treatment, CRUK and Macmillan Cancer Support act as fantastic allies for pharmacists. In this interview,…
Jackie Lewis, BPharm, MRPharmS, PhD of Lewis Pharmacy, Devon, UK discusses the evolution of cancer care in community pharmacies. Dr…
As the demand on healthcare services increases, novel and innovative ways to meet that demand need to be created. In…
Speaking from the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, Jackie Lewis, BPharm, MRPharmS, PhD…
Aziz Nazha, MD from the Cleveland Clinic discusses algorithm picks relevant variables and variables help predict survivability with myelodysplastic syndromes…
There are now many drugs available for the treatment of chronic lymphocytic leukemia (CLL); however, there is only limited data…
The optimal treatment for younger patients with relapsed/refractory chronic lymphocytic leukemia (CLL) depends on a number of factors, including what…
There are now many effective therapies to choose from for chronic lymphocytic leukemia (CLL). Thus, a recent area of therapeutic…
Richters transformation remains a challenge in chronic lymphocytic leukemia (CLL). In this interview, Matthew Davids, MD, of the Dana-Farber Cancer…
John M. Burke, MD from Rocky Mountain Cancer Centers discusses Atezolizumab + Bendamustine & Obinutuzumab and no major safety signals…
Targeted therapies have revolutionized the treatment of cancer; however, under the selective pressures exerted by these therapies, tumor cells with…
TAK-659 is a novel FLT3 inhibitor in the initial trial stages for the treatment of acute myeloid leukemia (AML). Interestingly,…
Although our knowledge of the underlying genetic causes of acute myeloid leukemia (AML) and their consequent molecular results has progressed…
In patients whose cancer is primarily caused by a specific mutation, tests which enable the determination of variant allele frequency…
Robert Z. Orlowski, MD, PhD, from The University of Texas MD Anderson Cancer Center discusses combinations well tolerated in multiple…
Sattva S. Neelapu, MD, from the University of Texas MD Anderson Cancer Center discusses how Axi-Cel is a milestone for…
Alok Khorana, MD of the Cleveland Clinic discusses the prevalence and consequences of VTE and increased chance of fatality and…
Joseph M. Connors, MD, FRCPC from The BC Cancer Agency Research Centre discusses checkpoint inhibitors in Hodgkin’s lymphoma and immune…
Although great strides have been made in cancer treatment and diagnosis, in many types of cancer these aspects are still…
There is a constant need for new knowledge discovery in cancer biology; we do not yet fully understand the underlying…
Modern machinery learning techniques allow for the processing of large quantities of cancer images, at a much faster rate than…
Artificial neural networks that can process information have existed for a long time. However, in recent years greater computing power…
Although there are few data sets available to researchers in cancer imaging compared with other fields, experts are able to…
When studying patient data, many fields of cancer medicine will have large databases containing information from tens of thousands of…
The immunoscore is a predictive tool that looks at a cancer patients adaptive immunity to predict survival and recurrence, amongst…
An immunoscore is an evaluative test of a cancer patients adaptive immune activity towards their tumor, and can predict survival,…
The immunoscore is a predictive tool that scores cancer patients based on an evaluation of their adaptive immunity. In this…
It is important that we have accurate models for the risk stratification of cancer patients, in order to determine how…
There are many ways of predicting cancer recurrence and survival; these include pathology-based tests, such as tumor grade, molecular markers,…